Lucerastat
- Generic Name
- Lucerastat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H21NO4
- CAS Number
- 141206-42-0
- Unique Ingredient Identifier
- GVS3YDM418
- Background
Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT03737214
- Locations
- 🇺🇸
University of Utah - Division of Medical Genetics, Clinical Genetics Research, Salt Lake City, Utah, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇺🇸University of Pennsylvania - Dept of Medicine, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT03425539
- Locations
- 🇺🇸
Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03380455
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Actelion
- Target Recruit Count
- 37
- Registration Number
- NCT02944474
- Locations
- 🇬🇧
Investigator Site, Edinburgh, United Kingdom
A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Actelion
- Target Recruit Count
- 39
- Registration Number
- NCT02944487
- Locations
- 🇬🇧
Investigator Site, Tranent, United Kingdom
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
- Conditions
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02930655
- Locations
- 🇩🇪
Investigator Site, Würzburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.